ArticleDermatology (Basel, Switzerland)2025
X-Ray Therapy of Skin Cancer at Critical Facial Sites: Results of a Tertiary Referral Center.
Article in Dermatology (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic management of skin cancer (SC) in the "H-area" of the face is challenging due to the demands of function, cosmesis, and efficacy.
objectiveTo evaluate the efficacy and safety of superficial radiotherapy (RT) for SC in the "H-area" of the face and to identify predictors of recurrence.
methodsRetrospective analysis of patients with SC in the "H-area" of the face treated with superficial RT at the University Hospital of Zurich, Switzerland, between 2010 and 2021. The study included cases of basal cell carcinoma (BCC), squamous cell carcinoma (SCC), in situ SCC (isSCC), lentigo maligna melanoma (LMM), lentigo maligna (LM), and primary cutaneous T/B-cell lymphoma.
resultsWe identified 546 lesions in 382 patients. Estimated relapse rates at 5 years were lowest for SCC (3.2%), isSCC (1.9%), and BCC (9.7%), while LMM and LM showed estimated relapse rates of 28.9% and 35.0%, respectively. Significant predictive factors for overall recurrence were increased Common Terminology Criteria for Adverse Events (CTCAE) grades with a hazard ratio (HR) of 1.9 (1.1-3.4) and the treatment of secondary lesions with an HR of 2.6 (1.4-5.1).
conclusionRT is a valuable treatment option for malignant skin tumors, especially non-melanoma SC, in high-risk areas, including the facial "H-area," providing favorable results with minimal side effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.